SEC Form 4 · accession 0001437749-19-002255
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jed Latkin
Officer — CEO, COO & CFO · Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 6:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | — | Feb 7, 2019 | A | 1,000,000 | A | — | Feb 7, 2029 | Common Stock | 1,000,000 | 2,065,000 | D |
Explanation of responses
- F1333,334 options with a strike price of $0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.50 per share; 333,333 options with a strike price of $0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.70 per share; and 333,333 options with a strike price of $0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share.